McKesson (MCK) Stock Forecast & Price Target

McKesson is well positioned to compound value because its leadership in U.S. pharmaceutical wholesale, alongside Cencora and Cardinal Health, gives it exposure to a market where specialty drugs are becoming a larger share of spending, expected to reach 55+% by 2028, with 7-8 of 10 new approvals classified as specialty and 20+ CGT therapies expected in 2026. Its vertically integrated strategy is also strengthening economics by expanding beyond pure distribution into higher-margin patient support, data analytics, and direct-to-patient delivery, while robust GLP-1 demand and contributions from generics and biosimilars support stronger topline growth and slight margin expansion. Operationally, >99% order accuracy, cold-chain automation, and disciplined sustainability execution, including 72% progress toward FY2032 emissions goals and 32% renewable electricity use as of FY2026, reinforce efficiency, reduce waste, and differentiate the franchise.

McKesson is facing a strained near-term setup because the BRIDGE program’s contribution was already embedded in FY2027 guidance, limiting upside from what management called a stronger-than-expected start. The bigger issue is that GLP-1 prior authorizations contribute 9.5%-11.5% of RxTS revenue, or roughly $560-$660M, yet employer coverage erosion is accelerating, with 6% of large employers dropping coverage in 2026 and another 10% planning to do so in 2027. At the same time, the 2028 IRA negotiations could cut prices 40%-60% on about $28B of Medicare drug spend, while razor-thin distribution margins and competitive pressure make it difficult to offset lost volume or protect 11%-15% operating income growth.